Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers. (January 2019)

• Record Type: Journal Article
• Authors: Downs, Bradley; Sherman, Simon; Cui, Jian; Kim, Yeong C.; Snyder, Carrie; Christensen, Maria; Luo, Jiangtao; Lynch, Henry; Wang, San Ming
• Is Part Of: European journal of cancer. Volume 107(2019)
• Page Start: 68
• Page End: 78
• Publication Date: 2019-01
• Subjects: BRCA1 -- Breast cancer -- Cancer resistance -- Exome -- Variation; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2018.10.022
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Purpose: The presence of pathogenic germline mutation in BRCA1 gene is considered as the most penetrant genetic predisposition for breast cancer. However, a portion of BRCA1 mutation carriers never develops breast cancer throughout their lifetime. This phenomenon is called incomplete penetrance. Genetic factor is proposed to contribute to this phenomenon, but the details regarding the genetic factor remain elusive. BRCA1 mutations were inherited from the ancestors of the mutation carrier families during human evolution, and their presence is a consistent threat to the survival of the mutation carrier population. In the present study, we hypothesize that evolution could positively select genetic components in the mutation carrier population to suppress the oncogenesis imposed by the predisposition. Experimental design: To test our hypothesis, we used whole exome sequencing to compare germline variation of all genes in pairs of breast cancer–unaffected and breast cancer–affected BRCA1 mutation carriers, each pair was from the same family carrying the same BRCA1 mutation. Results: We identified a group of 'beneficial' variants enriched in the breast cancer–unaffected carrier group. These were the common variants in human population distributed in multiple genes involved in multiple functionally important pathways. We found a single-nucleotide polymorphism, rs3735400 located in ANLN gene, which plays an essential role in controlling cytokinesis and is often found to be overexpressed in cancer. The carriers of this variant had lower cumulative risk of developing breast cancer; overexpression of the variant-containing ANLN decreased ANLN nuclear localization suppressed expression of the variant-containing ANLN, and decreased the cellular proliferation respectively. Conclusion: Our findings support our hypothesis that common genetic variants can be evolutionarily selected in BRCA1 mutation carrier population to counterpart the oncogenic effects imposed by mutation predisposition in BRCA1, contributing to the incomplete penetrance. Highlights: The study analyzed gene variation between pairs of cancer-unaffected and -affected familial members inherited with the same mutations in BRCA1, and observed the presence of a set of common "beneficial" variants enriched in the cancer-unaffected group. The study highlights that the beneficial variants counterpart the oncogenic effects of BRCA1 mutation, contributing to incomplete penetrance.